By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Boehringer Ingelheim Corporation 

P.O. Box 368
900 Ridgebury Road
Ridgefield  Connecticut  06877-0368  U.S.A.
Phone: 203-798-99-88 Fax: 203-791-62-34


Company News
Boehringer Ingelheim Corporation Release: OFEV® (Nintedanib*) Approved In The EU For The Treatment Of IPF 1/19/2015 11:17:46 AM
Boehringer Ingelheim Corporation Considering Sale of Its U.S.-Based Generics Biz 1/15/2015 5:58:51 AM
Sanofi (SAN.PA), Boehringer Ingelheim Corporation Forge Biologics Pact 1/15/2015 5:57:39 AM
Boehringer Ingelheim Corporation And Yale University Collaborate To Investigate Novel Immunotherapy Targets Across Several Therapeutic Areas 1/14/2015 10:36:02 AM
Boehringer Ingelheim Corporation And Vanderbilt University Join Forces To Develop New Ras Inhibitors For Cancer Treatment 1/14/2015 10:28:46 AM
Boehringer Ingelheim Corporation And BioMed X Collaborate To Discover New Epigenetic Regulators Of COPD 1/5/2015 7:11:57 AM
Big Pharmas Like Johnson & Johnson (JNJ), Boehringer Ingelheim Corporation. Eli Lilly (LLY), and Roche (RHHBY) are Shedding Jobs in Korea 12/22/2014 7:01:09 AM
nanoPET Pharma Initiates R&D Partnership With Boehringer Ingelheim Corporation 12/1/2014 3:30:21 PM
Boehringer Ingelheim Corporation, Wellpoint, And HealthCore Announce First Project Under Multi-Year Research Collaboration 11/14/2014 10:58:36 AM
Boehringer Ingelheim Corporation Passes on Anthera, Inc.'s CV Antibody Option 11/13/2014 6:58:48 AM